Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: Transplant Cell Ther. 2021 Feb 17;27(5):434.e1–434.e6. doi: 10.1016/j.jtct.2021.02.013

TABLE 2.

Five- and ten-year cumulative incidence rates with 95% confidence intervals (CI) of kidney outcomes among HCT vs. comparison groups (non-HCT cancer survivors and the general population [DOL])

HCT
 Non-HCT
 DOL
Outcome No. events 5y (95% CI) 10y (95% CI) No. events 5y (95% CI) 10y (95% CI) No. events 5y (95% CI) 10y (95% CI)
Acute kidney failure 142 5.2 (4.2–6.3) 9.4 (7.9–11.2) 364 5.0 (4.4–5.7) 7.7 (6.9–8.6) 258 0.8 (0.7–1.0) 1.8 (1.6–2.1)
Chronic kidney disease 94 3.0 (2.3–4.0) 5.7 (4.5–7.1) 234 3.5 (3.0–4.1) 5.0 (4.3–5.7) 176 0.6 (0.4–0.7) 1.2 (1.0–1.4)
All kidney disease 190 6.9 (5.7–8.2) 12.4 (10.6–14.3) 510 7.3 (6.6–8.1) 10.7 (9.8–11.7) 367 1.2 (1.0–1.4) 2.5 (2.2–2.8)

DOL, Department of Licensing; HCT, hematopoietic cell transplantation